Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re EGM

13 Aug 2010 16:24

RNS Number : 0819R
Ark Therapeutics Group PLC
13 August 2010
 



ARK THERAPEUTICS GROUP PLC (the "Company")

 

POSTPONEMENT OF EXTRAORDINARY GENERAL MEETING ("EGM")

 

In light of representations made to the Company by a number of shareholders, in part prompted by unavailability over the summer holiday season, the Board has taken the decision to reschedule the EGM from 11.00 a.m. on 19 August 2010 to 12 noon on 6 September 2010. The location of the EGM will not change.

 

This will, in addition, allow the Board to convene and consider in detail the next steps in the implementation of its strategy, informed by its discussions with Iain Ross who has spent the recent weeks working alongside management undertaking a wholesale review of the Group's business and operations. The Board wishes to inform shareholders of the outcome of those deliberations in advance of the EGM and will, therefore, provide a further update as part of its half-yearly report, which is scheduled to be released on 25 August.

 

In accordance with the Articles, the Board shall provide details of the postponed EGM in two UK national newspapers.

 

EGM Deadline and Voting Formalities

 

The current forms of proxy remain valid. The new deadline for the written forms of proxy must be submitted by 12 noon on 2 September 2010. Forms of proxy that have been validly submitted by shareholders to date shall remain valid for the postponed EGM.

 

Save as expressly stated in this document, the contents of the original notice of extraordinary general meeting, including without limitation the business to be conducted at the meeting and the Board's recommendation, shall be unchanged. Words and expressions defined in the original notice for the EGM, shall, unless the context otherwise requires, have the same meaning when read in this document. All other terms and provisions of the Company's original notice for the EGM along with the forms of proxy (all dated 28 July 2010) shall apply. For further details and copies of the relevant documents, please go to www.arktherapeutics.com.

 

A letter has been sent to the Company's shareholders setting out the information above, two copies of which have been sent to the UK Listing Authority Document Viewing Facility and will be available for viewing shortly.

 

 

 

For further information:

 

Ark Therapeutics Group plc

Tel: + 44 (0)20 7388 7722

Martyn Williams, CEO

 

Andrew Christie, Chairman

 

 

 

Financial Dynamics

Tel: +44 (0)20 7831 3113

Ben Atwell

 

Susan Quigley

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDIXDBBGGX
Date   Source Headline
10th Mar 20101:21 pmRNSEPT Disclosure
10th Mar 201011:52 amRNSEPT Disclosure
10th Mar 20107:00 amRNSFinal Results
9th Mar 20107:00 amRNSResearch Update
8th Mar 20105:34 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSResearch Update
19th Feb 20107:00 amRNSRe Agreement
16th Feb 20104:40 pmRNSSecond Price Monitoring Extn
16th Feb 20104:35 pmRNSPrice Monitoring Extension
11th Feb 201011:37 amRNSDirector/PDMR Shareholding
5th Feb 20104:35 pmRNSPrice Monitoring Extension
29th Jan 20103:23 pmRNSTotal Voting Rights
28th Jan 201011:05 amRNSNotice of Results
28th Jan 20107:02 amRNSResearch Update
28th Jan 20107:00 amRNSResearch Update
20th Jan 20103:51 pmRNSEmployee Benefit Trust
5th Jan 20107:00 amRNSArk files for re-examination of Cerepro
22nd Dec 20094:41 pmRNSSecond Price Monitoring Extn
22nd Dec 20094:35 pmRNSPrice Monitoring Extension
18th Dec 200911:56 amRNSEMEA recommendation on Cerepro
15th Dec 20092:29 pmRNSHolding(s) in Company
3rd Dec 20092:41 pmRNSBlocklisting Interim Review
3rd Dec 20092:35 pmRNSHolding(s) in Company
24th Nov 20094:04 pmRNSHolding(s) in Company
11th Nov 20097:00 amRNSInterim Management Statement
14th Oct 20097:00 amRNSResearch Update
2nd Oct 200911:04 amRNSHolding(s) in Company
30th Sep 200910:51 amRNSHolding(s) in Company
29th Sep 20094:32 pmRNSHolding(s) in Company
4th Sep 20097:00 amRNSResearch Update
1st Sep 200912:08 pmRNSDirector/PDMR Shareholding
26th Aug 20097:00 amRNSResearch Update
26th Aug 20097:00 amRNSHalf Yearly Report
13th Jul 20097:00 amRNSArk launches Kerraglove woundcare device
1st Jul 20097:00 amRNSRe Agreement
26th Jun 20092:15 pmRNSHolding(s) in Company
24th Jun 20097:00 amRNSManufacturing Update
17th Jun 20097:00 amRNSRe Agreement
3rd Jun 200911:47 amRNSBlocklisting Interim Review
21st May 20097:00 amRNSTrinam Phase III Study Enrols First Patient
18th May 20097:00 amRNSInterim Management Statement
15th May 20097:00 amRNSCerepro Named Patient Supply approved in Finland
13th May 20094:41 pmRNSSecond Price Monitoring Extn
13th May 20094:35 pmRNSPrice Monitoring Extension
12th May 20097:00 amRNSDirector/PDMR Shareholding
6th May 20094:40 pmRNSSecond Price Monitoring Extn
6th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20097:00 amRNSTrinam(R) Awarded Fast Track Status by FDA
30th Apr 20094:01 pmRNSTotal Voting Rights
30th Apr 200912:00 pmRNSPrestigious European Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.